Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion.

Yadi Wu,Jiong Deng,P. Rychahou,S. Qiu,B. Evers,Binhua P. Zhou

DOI: https://doi.org/10.1016/j.ccr.2009.03.016

IF: 50.3

2009-05-05

Cancer Cell

Abstract:

What problem does this paper attempt to address?

The future of the firewall

S. Gold

DOI: https://doi.org/10.1016/S1353-4858(11)70015-0

2011-02-01

Network Security

Abstract:
The prevalence and predictors of metabolic dysfunction‐associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults

Brandon J. Perumpail,Richie Manikat,Karn Wijarnpreecha,George Cholankeril,Aijaz Ahmed,Donghee Kim

DOI: https://doi.org/10.1002/jpn3.12219

2024-04-17

Journal of Pediatric Gastroenterology and Nutrition

Abstract:Objectives We investigated the current prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and fibrosis/cirrhosis and identified at‐risk populations for MASLD and MASLD‐related fibrosis among US adolescents and young adults in the United States. Methods Utilizing the National Health and Nutrition Examination Survey 2017−2020, the prevalence of MASLD and fibrosis/cirrhosis was assessed via controlled attenuation parameter (CAP) score and liver stiffness measurements by transient elastography in participants aged 12−29 years with at least one cardiometabolic criteria and absence of other chronic liver disease. Multivariable logistic regression was performed to determine predictors of MASLD and MASLD‐related fibrosis. Results The overall prevalence of MASLD was 23.9% (95% CI: 21.3−26.5 for CAP ≥ 263 dB/m) and 17.3% (95% CI: 14.7−20.0 for ≥285 dB/m), respectively. The prevalence of fibrosis and cirrhosis in MASLD was 11.0% and 3.1%, respectively. When categorized by age, the prevalence of MASLD varied from 16.8% (of which 6.2% [fibrosis], 1.8% [cirrhosis]) in early and middle adolescents (12−17 years), to 25.5% (11.8% [fibrosis], 4.8% [cirrhosis]) in late adolescents and young adults (18−24 years), and to 30.4% (of which 13.2% [fibrosis] and 2.1% [cirrhosis]) in older young adults (25−29 years). The independent predictors for MASLD included male sex, Hispanic, non‐Hispanic Asian, body mass index, and low HDL‐cholesterol. In contrast, diabetes and body mass index were associated with an increased risk of fibrosis in individuals with MASLD. Conclusions The prevalence of MASLD and related fibrosis in adolescents and young adults in the United States has reached a significant level, with a substantial proportion of cirrhosis.

pediatrics,gastroenterology & hepatology,nutrition & dietetics
Amyloid or tau: the chicken or the egg?

D. Mann,J. Hardy

DOI: https://doi.org/10.1007/s00401-013-1162-1

IF: 15.887

2013-08-08

Acta Neuropathologica

Abstract:
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States

Samer Gawrieh,Eduardo Vilar-Gomez,Tinsay A Woreta,Jordan E Lake,Laura A Wilson,Jennifer C Price,Susanna Naggie,Richard K Sterling,Sonya Heath,Kathleen E Corey,Edward R Cachay,Veeral Ajmera,James Tonascia,Mark S Sulkowski,Naga Chalasani,Rohit Loomba

DOI: https://doi.org/10.1111/apt.17849

Abstract:Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD. Aims: To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF). Methods: PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration-controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa. The prevalence of SLD, MASLD, metabolic dysfunction and alcohol-associated liver disease (MetALD), ALD, cryptogenic (cSLD), CSF and AF were determined. Uni- and multivariate logistic regression models were used to assess factors associated with MASLD and CSF risk. Results: Of 1065 participants, 74% were male, mean (SD) age 51.6 ± 11.9 years, 46% non-Hispanic Black and 74% with undetectable HIV RNA. The prevalence of SLD was 52%, MASLD 39%, MetALD 10%, ALD 3%, CSF 15% and AF 4%. Only 0.6% had cSLD. Black race was protective whereas obesity, ALT and AST levels were associated with increased risk of MASLD and CSF in MASLD. HIV or antiretroviral therapy did not affect MASLD risk. Conclusions: MASLD and MetALD are the dominant causes of SLD in PWH, affecting almost half. Application of the new nomenclature resulted in minimal change in the proportion of patients with MASLD who would have been diagnosed previously with NAFLD.
Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population

Carolin V. Schneider,Kai Markus Schneider,Anastasia Raptis,Helen Huang,Christian Trautwein,Rohit Loomba

DOI: https://doi.org/10.1111/apt.17958

IF: 9.524

2024-03-20

Alimentary Pharmacology & Therapeutics

Abstract:The prevalence of at‐risk MASH was estimated to be approximately 0.6% in the general population. These patients demonstrated severe metabolic and inflammatory profiles and are eligible for treatment with pharmacologic therapy when approved by regulatory authorities. The graphical abstract was created with biorender.com. Summary Background The prevalence of at‐risk metabolic dysfunction‐associated steatohepatitis (at‐risk MASH) has not been systematically assessed. Aim To delineate the prevalence of at‐risk MASH in a large population‐based cohort. Methods We conducted a cross‐sectional analysis of 40,189 patients in the UK Biobank who underwent liver MRI. Hepatic steatosis was determined by proton density fat fraction (PDFF) ≥5%. Based on AASLD criteria, participants were classified as alcohol‐associated steatotic liver disease (ALD), metabolic dysfunction‐associated steatotic liver disease (MASLD), combined metabolic alcoholic liver disease (MetALD) and at‐risk MASH. Results Among 40,189 patients, 10,886 (27.0%) had a PDFF ≥5%, indicating SLD. Among patients with SLD, 1% had ALD, 89.0% had MASLD, 7.9% had MetALD and 2.2% had at‐risk MASH. The at‐risk MASH group, which included 0.6% of the general population, had the highest mean liver fat on MRI and the highest BMI. Serum biomarkers highlighted increased inflammation and metabolic changes in at‐risk MASH. The prevalence of MASLD was significantly higher among men with a BMI ≥30 kg/m2. Non‐obese women showed only a 12% risk of MASLD. Conversely, MetALD had similar prevalence in obese men and women and was absent in non‐obese women. Conclusions MASLD is prevalent among patients with elevated PDFF on MRI. There are different sex‐ and BMI‐specific prevalence of different steatotic liver disorders. At‐risk MASH demonstrates the most severe metabolic and inflammatory profiles. This study provides novel estimates for the at‐risk MASH population that will be eligible for treatment with pharmacologic therapy when approved by regulatory authorities.

pharmacology & pharmacy,gastroenterology & hepatology
Incidence of metabolic dysfunction‐associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study

Kunhee Kim,Yaeji Lee,Jae Seung Lee,Mi Na Kim,Beom Kyung Kim,Seung Up Kim,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Inkyung Jung,Hye Won Lee

DOI: https://doi.org/10.1111/jgh.16755

2024-10-01

Journal of Gastroenterology and Hepatology

Abstract:Background and Aim The prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasing worldwide, coinciding with aging population. However, limited studies have evaluated its incidence and progression to advanced fibrosis in the elderly population. Therefore, our study aimed to investigate the incidence of MASLD and advanced fibrosis in this age group. Methods We included 878 686 individuals aged ≥60 years from the Korea National Health Insurance Service‐Senior cohort. After excluding participants with preexisting MASLD, 329 388 individuals were finally analyzed. Participants were categorized into four groups based on the presence of overweight/obesity and additional risk factors (aRF) included in the cardiometabolic diagnostic criteria of MASLD. Results The overall incidence of MASLD was 1.94 per 100 person‐years, and the incidence of advanced fibrosis in MASLD patients was 1.78 per 100 person‐years. MASLD development was significantly higher in overweight/obese patients (2.65 per 100 person‐years) compared to lean patients (1.09 per 100 person‐years), and this trend persisted after stratification by the presence of aRF. Similarly, the incidence of advanced fibrosis among MASLD patients was higher in overweight/obese individuals (2.06 per 100 person‐years) compared to lean counterparts (0.87 per 100 person‐years), irrespective of aRF. Conclusions The lower incidence of MASLD in the elderly population compared to the general population underscores the importance of identifying age‐specific risk factors. Overweight/obesity emerged as a robust predictor of MASLD development and advanced fibrosis. Additionally, the presence of additional cardiometabolic risk factors further increased the risk of incident MASLD and advanced fibrosis among the elderly.

gastroenterology & hepatology
The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD

Yasmina Chouik,Adrien Aubin,Marianne Maynard‐Muet,Bérénice Segrestin,Laurent Milot,Valérie Hervieu,Fabien Zoulim,Emmanuel Disse,Massimo Levrero,Cyrielle Caussy

DOI: https://doi.org/10.1002/oby.24033

IF: 9.298

2024-05-05

Obesity

Abstract:Objective Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely associated with obesity. We aimed to assess the impact of obesity on the performance of different noninvasive tests, including liver stiffness measurement (LSM) and Agile3+ (A3+), to detect advanced fibrosis (AF) in a population of patients with MASLD encompassing a wide range of BMI values. Methods A total of 479 patients with MASLD were consecutively included (Lyon Hepatology Institute). Clinical data and noninvasive tests, including FibroTest, LSM, A3+, Fibrosis‐4 (FIB‐4), magnetic resonance elastography, and liver biopsies, were collected. AF was determined by a composite endpoint, i.e., histological stage ≥ F3, overt diagnosis of cirrhosis by magnetic resonance elastography, or concordant LSM ≥ 9.6 kPa and FibroTest ≥ F3. Results The median BMI was 35.0 kg/m2, and the prevalence of AF was 28.6%. Patients with BMI ≥ 35 versus <35 had a lower proportion of AF, i.e., 19.3% versus 38.1% (p

endocrinology & metabolism,nutrition & dietetics
Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents

Guang-Xia Shi,Yun-Song Qian,Chun-Mei Jiang,Zhen-Zhen Liu,Xi Yang,Yi-Wen Xu,Su-Su Jin,Jin-Guo Chu,Guo-Qing Qian,Nai-Bin Yang

DOI: https://doi.org/10.1038/s41598-024-76922-9

IF: 4.6

2024-10-30

Scientific Reports

Abstract:We aim to evaluate the prevalence of steatotic liver disease (SLD) in United States (US) adolescents and explore whether metabolic dysfunction-associated steatotic liver disease (MASLD) can identify individuals with clinically significant fibrosis (CSF) in this study. The prevalence of SLD and its categories, including MASLD, metabolic dysfunction and alcohol associated liver disease (MetALD), alcohol related liver disease (ALD) and other SLD were determined. Weighted multivariable logistic regression analysis was conducted to evaluate the association between MASLD and CSF in adolescents with SLD. Among the total 1,446 US adolescents, SLD was present in 291 (20.1%) of individuals, including 260 (17.9%) for MASLD, 9 (0.6%) for MetALD and 5 (0.3%) for ALD. Only 58 (4%) had CSF. Patients with SLD showed a higher prevalence of CSF (9.6% vs. 2.6%, p < 0.001). Among patients with SLD, 89.3% met the MASLD criteria. The risk of CSF in patients with MASLD was not significantly different (odds ratio [OR] = 1.07, 95% confidence interval [CI] = 0.30–3.83, p = 0.9180) compared with those without MASLD. MASLD was met by most of the US adolescents with SLD. Moreover, MASLD was not associated with higher prevalence of CSF among adolescents with SLD.

multidisciplinary sciences
Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function

Carolina Villarroel,Gres Karim,Mantej Sehmbhi,Jake Debroff,Ilan Weisberg,Amreen Dinani

DOI: https://doi.org/10.1016/j.gastha.2023.09.008

2023-09-23

Abstract:Background and aims: The large global population of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been shown to have an association with chronic kidney disease (CKD) due to a host of proposed mechanisms, one of which being lipoprotein dysmetabolism. Furthermore, metabolic comorbidities have been concurrently prevalent in MASLD and CKD independently. This study aimed at analyzing risk and predictive traits among an obese population for both MASLD and CKD. Methods: A retrospective chart review of 546 obese patients with a diagnosis of either MASLD or metabolic dysfunction-associated steatohepatitis between January 2020 and June 2021 was performed. Markers of liver and kidney function in addition to demographic data and renoprotective medications were recorded. Both univariable and multivariable linear regression analyses were performed to understand possible associations between MASLD markers, renal function, and markers of metabolic derangements. Results: Univariate analysis revealed that increased age (P < .001), elevated alanine aminotransferase (defined as alanine aminotransferase ≥ 30 IU/L, P = .01), low albumin (P = .011), and increasing fibrosis-4 (FIB-4) (P = .005) were statistically associated with a reduced renal function. A reduction in glomerular filtration was associated with an increase in FIB-4 (effect size [beta] of a one-unit increase in glomerular filtration on FIB-4 = -0.013, P < .001) in univariate linear regression. In multivariate linear regression, type 2 diabetes (T2D) was independently associated with increased liver fibrosis (effect size of T2D on FIB-4 = 0.387925, P < .02). Conclusion: Our study shows that in a patient population with obesity and a diagnosis of MASLD, advanced fibrosis is independently associated with reduced renal function.
Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care

Ted G. Xiao,Lauren Witek,Richa A. Bundy,Adam Moses,Corey S. Obermiller,Andrew D. Schreiner,Ajay Dharod,Mark W. Russo,Sean R. Rudnick

DOI: https://doi.org/10.1007/s11606-024-08955-9

IF: 5.7

2024-07-26

Journal of General Internal Medicine

Abstract:Abstract Background and Aims Severity of fibrosis is the driver of liver-related outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), and non-invasive testing such as fibrosis-4 (FIB-4) score is utilized for risk stratification. We aimed to determine if primary care patients at risk for MASLD and advanced fibrosis were evaluated with subsequent testing. A secondary aim was to determine if at-risk patients with normal aminotransferases had advanced fibrosis. Methods Primary care patients at increased risk for MASLD with advanced fibrosis ( n = 91,914) were identified using previously established criteria. Patients with known alternative/concomitant etiology of liver disease or cirrhosis were excluded. The study cohort included patients with calculated FIB-4 score in 2020 ( n = 52,006), and stratified into low, indeterminate, and high likelihood of advanced fibrosis. Among those at indeterminate/high risk, rates of subsequent testing were measured. Results Risk stratification with FIB-4 characterized 77% ( n = 40,026) as low risk, 17% ( n = 8847) as indeterminate, and 6% ( n = 3133) as high risk. Among indeterminate/high-risk patients ( n = 11,980), 78.7% ( n = 9433) had aminotransferases within normal limits, 0.95% ( n = 114) had elastography, and 8.2% ( n = 984) were referred for subspecialty evaluation. Conclusion In this cohort of primary care patients at risk for MASLD with fibrosis, the FIB-4 score identified a substantial proportion of indeterminate/high-risk patients, the majority of which had normal aminotransferase levels. Low rates of subsequent testing were observed. These data suggest that a majority of patients at increased risk for liver-related outcomes remain unrecognized and highlight opportunities to facilitate their identification.

medicine, general & internal,health care sciences & services
Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score

Pimsiri Sripongpun,Apichat Kaewdech,Prowpanga Udompap,W Ray Kim

DOI: https://doi.org/10.1016/j.jhepr.2024.101127

2024-06-03

Abstract:Background & aims: The new nomenclature of steatotic liver disease (SLD) was recently launched with sub-classifications of metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Herein, we aimed to evaluate the characteristics and long-term outcomes associated with these subgroups and the utility of non-invasive biomarkers. Methods: Using NHANES III (the third National Health and Nutrition Examination Survey) and linked mortality data, all adult participants with available ultrasonographic liver steatosis status were included. Those with viral hepatitis, incomplete data on alcohol consumption, cardiometabolic risk, and missing data that hindered Steatosis-associated Fibrosis Estimator (SAFE) score calculation were excluded. The characteristics of those without SLD (no steatosis on ultrasound), MASLD, MetALD, and ALD were compared. Overall survival (OS) was determined and SAFE score strata were applied to SLD subgroups. Results: A total of 9,939 participants were eligible; 64% had no SLD, while 30%, 2.3%, and 1% had MASLD, MetALD, and ALD, respectively. A higher proportion of men, as well as active smokers, was observed in the MetALD and ALD groups compared to the MASLD group. Diabetes was more prevalent in the MASLD group than in the MetALD and ALD groups. The ALD subgroup had significantly lower OS than the MASLD group (p = 0.004), but the MetALD did not (p = 0.165). SAFE score strata meaningfully differentiated OS of all SLD subgroups. Conclusions: MASLD accounted for the largest proportion of SLD. MetALD shared the characteristics of both MASLD and ALD. The ALD subgroup had a significantly lower OS than the MASLD subgroup but there was no difference between MetALD and MASLD. The SAFE score can be used to stratify long-term outcomes in all SLD subgroups. Impact and implications: "Steatotic liver disease (SLD)" is a recently introduced term covering three subgroups: MASLD (metabolic dysfunction-associated SLD), MetALD (MASLD with increased alcohol intake), and ALD (alcohol-related liver disease). We explored the characteristics and outcomes of these subgroups among the US population. We found that MASLD was far more common than MetALD and ALD, but all subgroups shared cardiometabolic risk factors. The ALD subgroup has the worst survival, pointing to the synergistic effect of alcohol and metabolic dysfunction. In addition, the SAFE (Steatosis-associated Fibrosis Estimator) score might be a useful non-invasive test to stratify long-term risk in all three SLD subgroups.
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis

Mohammad Zamani,Shaghayegh Alizadeh-Tabari,Veeral Ajmera,Siddharth Singh,Mohammad Hassan Murad,Rohit Loomba

DOI: https://doi.org/10.1016/j.cgh.2024.08.020

IF: 13.576

2024-09-22

Clinical Gastroenterology and Hepatology

Abstract:Background & Aims Limited data exist regarding the estimate of the prevalence of advanced liver fibrosis and cirrhosis in the general population. Therefore, we conducted a systematic review and meta-analysis to evaluate the global prevalence and risk factors of advanced fibrosis and cirrhosis. Methods We searched Embase, PubMed, Scopus, and Web of Science from inception to April 30 2024, with no language restriction. We included cross-sectional studies reporting the prevalence of advanced liver fibrosis and/or cirrhosis in a sample of at least 100 individuals aged ≥18 years from the general population. Subjects with cirrhosis were included in the advanced fibrosis group. The pooled prevalence proportions utilizing a random-effects model and 95% confidence intervals (CIs) were estimated using global data. Results A total of 46 studies fulfilled the eligibility criteria, comprising approximately 8 million participants from 21 countries. The pooled prevalence rates of advanced liver fibrosis and cirrhosis in the general population were 3.3% (95% CI, 2.4%–4.2%) and 1.3% (95% CI, 0.9%–1.7%) worldwide, respectively. A trend was observed for an increase in the prevalence of advanced fibrosis ( P = .004) and cirrhosis ( P = .034) after 2016. There were significant geographic variations in the advanced fibrosis and cirrhosis prevalence at continental and national levels ( P < .0001). Potential risk factors for cirrhosis were viral hepatitis, diabetes, excessive alcohol intake, obesity, and male sex. Conclusions The prevalence of advanced fibrosis and cirrhosis is considerable and increasing worldwide with significant geographic variation. Further research is needed to better understand the risk factors and how to mitigate them worldwide to address the growing global burden of cirrhosis.

gastroenterology & hepatology
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up

Yuji Ogawa,Wataru Tomeno,Yasushi Imamura,Masaru Baba,Takato Ueno,Takashi Kobayashi,Michihiro Iwaki,Asako Nogami,Takaomi Kessoku,Yasushi Honda,Kazuo Notsumata,Hirotoshi Fujikawa,Megumi Kaai,Kento Imajo,Miwa Kawanaka,Hideyuki Hyogo,Mitsurou Hisatomi,Mamiko Takeuchi,Taku Hakamada,Takashi Honda,Miwa Tatsuta,Asahiro Morishita,Shigeru Mikami,Ken Furuya,Noriaki Manabe,Tomoari Kamada,Takumi Kawaguchi,Masato Yoneda,Satoru Saito,Atsushi Nakajima

DOI: https://doi.org/10.1111/hepr.14117

2024-10-05

Hepatology Research

Abstract:Prevalence of steatotic liver disease was 39.5%, with that of metabolic dysfunction‐associated steatotic liver disease at 28.7%. The FIB‐4 index is convenient but might not perform well as a primary screening tool for liver fibrosis in the general population. Aims The multisociety consensus nomenclature has introduced steatotic liver disease (SLD) with diverse subclassifications, which are metabolic dysfunction‐associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol‐associated steatotic liver disease (MetALD), alcohol‐associated liver disease (ALD), specific etiology, and cryptogenic. We investigated their prevalence, as per the new definition, in individuals undergoing health check‐ups. Additionally, we analyzed the distribution of Fibrosis‐4 (FIB‐4) index and vibration‐controlled transient elastography (VCTE)‐derived liver stiffness measurement (LSM) for MASLD. Methods In this cross‐sectional study, 6530 subjects undergoing a health check‐up in Japan were included. Conventional B‐mode ultrasound was carried out on all 6530 subjects, and those with MASLD underwent VCTE. Results The prevalence of SLD was 39.5%, comprising MASLD 28.7%, MetALD 8.6%, ALD 1.2%, specific etiology SLD 0.3%, and cryptogenic SLD 0.7%. Subjects with VCTE‐derived LSM ≥8 kPa constituted 2.1% of MASLD. FIB‐4 ≥1.3 showed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value for diagnosing VCTE‐derived LSM ≥8 kPa were 60.6%, 77.0%, 5.3%, and 98.9%, respectively. The referral rate to specialists was 23.8% using FIB‐4 ≥1.30. "FIB‐4 ≥1.3 in subjects <65 years and FIB‐4 ≥2.0 in subjects ≥65 years" showed higher PPV (6.7%) and lower referral rate (17.1%) compared with FIB‐4 ≥1.3, but the sensitivity (54.5%) did not show adequate diagnostic capability as a noninvasive test for diagnosing VCTE‐derived LSM ≥8 kPa. Conclusions Acknowledging the selection bias in hepatology centers, we undertook this prospective health check‐up study. Although the FIB‐4 index proves to be a convenient marker, it might not perform well as a primary screening tool for liver fibrosis in the general population (UMIN Clinical Trials Registry No. UMIN000035188).

gastroenterology & hepatology
Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients

Fernando Bril,Eddison Godinez Leiva,Romina Lomonaco,Sulav Shrestha,Srilaxmi Kalavalapalli,Meagan Gray,Kenneth Cusi

DOI: https://doi.org/10.20517/mtod.2022.08

2022-07-18

Metabolism and Target Organ Damage

Abstract:Aim: The optimal screening strategy for advanced liver fibrosis in overweight and obese patients is unknown. The aim of this study is to compare the performance of different strategies to select patients at high risk of advanced liver fibrosis for screening using non-invasive tools. Methods: All patients underwent: liver 1H-MRS and percutaneous liver biopsy (in those with nonalcoholic fatty liver disease [NAFLD]). Unique selection strategies were compared to determine the best screening algorithm: (A) A "metabolic approach": selecting patients based on HOMA-IR ≥ 3; (B) A "diabetes approach": selecting only patients with type 2 diabetes; (C) An "imaging approach": selecting patients with hepatic steatosis based on 1H-MRS; (D) A "liver biochemistry approach": selecting patients with elevated ALT (i.e., ≥ 30 IU/L for males and ≥ 19 IU/L for females); and (E) Universal screening of overweight and obese patients. FIB-4 index, NAFLD fibrosis score, and APRI were applied as screening strategies. Results: A total of 275 patients were included in the study. Patients with advanced fibrosis (n = 29) were matched for age, gender, ethnicity, and BMI. Selecting patients by ALT elevation provided the most effective strategy, limiting the false positive rate while maintaining the sensitivity compared to universal screening. Selecting patients by any other strategy did not contribute to increasing the sensitivity of the approach and resulted in more false positive results. Conclusion: Universal screening of overweight/obese patients for advanced fibrosis with non-invasive tools is unwarranted, as selection strategies based on elevated ALT levels lead to the same sensitivity with a lower false positive rate (i.e., fewer patients that would require a liver biopsy or referral to hepatology).
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States

Donghee Kim,Karn Wijarnpreecha,George Cholankeril,Aijaz Ahmed

DOI: https://doi.org/10.1111/apt.18011

IF: 9.524

2024-04-24

Alimentary Pharmacology & Therapeutics

Abstract:Summary Background Recently, a panel of multi‐society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction‐associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD). Aims We compared the impact of SLD, subtype of SLD, MAFLD and NAFLD on all‐cause and cause‐specific mortality. Methods A total of 7811 individuals in the third National Health and Nutrition Examination Survey and linked mortality through 2019 were analysed. SLD was defined based on ultrasonographic hepatic steatosis. SLD, subtype of SLD and MAFLD were defined using the proposed definitions. The Cox proportional hazard model assessed all‐cause/cause‐specific mortality. Results During a median follow‐up of 27.1 years, individuals with SLD and MAFLD experienced approximately 13%–23% higher risk of all‐cause mortality (hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 1.02–1.29 for SLD; HR: 1.23, 95% CI: 1.09–1.38 for MAFLD; HR: 1.13, 95% CI: 1.01–1.27 for metabolic dysfunction‐associated steatotic liver disease [MASLD]). Individuals with MetALD demonstrated a higher risk of all‐cause (HR: 1.68, 95% CI: 1.10–2.57) and cancer‐related mortality (HR: 2.40, 95% CI: 1.23–4.66). MASLD with advanced fibrosis had an increased risk of all‐cause mortality compared to MASLD without advanced fibrosis. Conclusions SLD, especially MASLD and MetALD, is associated with increased all‐cause mortality among adults in the US. Given this significant association between SLD or subtype of SLD (MASLD and MetALD) and all‐cause mortality, adopting the proposed SLD criteria may help identify a sub‐group of individuals with SLD who are at an increased risk for all‐cause mortality.

pharmacology & pharmacy,gastroenterology & hepatology
A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States

Nikita Mittal,Harris Siddiqi,Egbert Madamba,Lisa Richards,Ricki Bettencourt,Veeral Ajmera,Rohit Loomba

DOI: https://doi.org/10.1111/apt.17997

IF: 9.524

2024-04-10

Alimentary Pharmacology & Therapeutics

Abstract:Among adults aged ≥50 years with T2DM, the prevalence of MASLD, at‐risk MASH and cirrhosis is high, posing a significant risk for liver‐related morbidity and mortality. Approximately 14% of patients with T2DM may be candidates for pharmacologic therapies specific to MASH‐related fibrosis. Summary Background There are limited data on the prevalence and treatment of at‐risk metabolic dysfunction‐associated steatohepatitis (MASH) among patients with type 2 diabetes (T2DM) in the United States. Aim To estimate the prevalence of at‐risk MASH in a prospectively recruited cohort of adults with T2DM using new nomenclature endorsed by multiple societies. Methods This prospective study enrolled adults aged ≥50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023. Metabolic dysfunction‐associated steatotic liver disease (MASLD) was defined by an magnetic resonance imaging proton density fat fraction ≥5% and at least one metabolic risk factor without any other chronic liver disease or secondary cause for hepatic steatosis. Results We included 530 adult patients with T2DM. The mean (±SD) age and body mass index (BMI) were 64.4 (±8.1) years and 31.5 (±6.1) kg/m2, respectively. Among patients with T2DM, the prevalence of MASLD, at‐risk MASH and cirrhosis was 69.6%, 13.6% and 6.8%, respectively. Among patients with co‐existing T2DM and obesity, the prevalence of MASLD, at‐risk MASH and cirrhosis was 77.8%, 15.9% and 9.0%, respectively, and was higher than in participants without obesity (p

pharmacology & pharmacy,gastroenterology & hepatology
Treatment of acute colonic pseudoobstruction (Ogilvie's syndrome) with cisapride.

Colin MacColl,Keith L. MacCannell,Barry Baylis,Samuel S. Lee

DOI: https://doi.org/10.1016/0016-5085(90)90301-G

IF: 29.4

1990-03-01

Gastroenterology

Abstract:
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study

Aryoung Kim,Danbee Kang,Sung Chul Choi,Dong Hyun Sinn,Geum‐Youn Gwak

DOI: https://doi.org/10.1111/hepr.14126

2024-10-27

Hepatology Research

Abstract:Individuals with steatotic liver disease experience accelerated loss of skeletal muscle mass. Loss of skeletal muscle mass in steatotic liver disease patients is more pronounced when combined with metabolic dysfunction or increased alcohol intake. Aims Identifying risk factors for sarcopenia is important due to its significant effect on health. The association between sarcopenia and the newly proposed steatotic liver disease (SLD) and its subclassification has largely been unexplored. Methods This longitudinal cohort study included 67 905 adults who underwent at least two health checkup examinations. SLD participants were categorized as cryptogenic SLD, metabolic dysfunction‐associated SLD, metabolic dysfunction‐associated alcoholic liver disease, or alcoholic liver disease. Appendicular skeletal muscle mass (ASM) was evaluated by bioelectrical impedance analysis. Results The average duration of follow‐up was 5.9 years. The annual ASM change was −31.0 g (95% CI −32.3, −29.6) and −38.3 g (−40.3, −36.3) in participants without and with SLD, respectively. When assessed based on SLD severity, annual ASM loss was fastest in SLD participants with Fibrosis‐4 score ≥1.3, followed by those with Fibrosis‐4 score <1.3 and those without SLD. In multivariable adjusted analysis, annual ASM loss was fastest in participants with metabolic dysfunction‐associated alcoholic liver disease (−49.8 g; −93.1, −6.5), followed by those with metabolic dysfunction‐associated SLD (−24.7 g; −60.4, 11.1), and alcoholic liver disease (−24.4 g; −91.1, 42.3), and slowest in those with cryptogenic SLD (reference). This pattern was more pronounced in participants with Fibrosis‐4 score ≥1.3. Conclusion The loss of skeletal muscle mass was fastest in the participants with metabolic dysfunction‐associated alcoholic liver disease, followed by participants with metabolic dysfunction‐associated SLD, alcoholic liver disease, and cryptogenic SLD. Particular attention to prevent sarcopenia should be given to SLD patients with cardiometabolic risk factors or alcohol consumption, especially in patients with advanced fibrosis.

gastroenterology & hepatology
A Health Checkup-Based Cross-Sectional Study

Takao Miwa,Satoko Tajirika,Nanako Imamura,Miho Adachi,Ryo Horita,Tatsunori Hanai,Taku Fukao,Masahito Shimizu,Mayumi Yamamoto

DOI: https://doi.org/10.3390/jcm13041158

IF: 3.9

2024-02-19

Journal of Clinical Medicine

Abstract:This cross-sectional study examined the prevalence and characteristics of steatotic liver disease (SLD) based on a recently introduced nomenclature in the Japanese health checkup population. SLD was evaluated using liver ultrasonography, and participants were categorized into metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol associated steatotic liver disease (MetALD), alcohol-associated/related liver disease (ALD), and cryptogenic SLD groups. The prevalence and characteristics of the SLD subclasses were assessed, and subgroup analyses were conducted for the non-obese (body mass index [BMI] ≤ 25 kg/m2) and lean (BMI ≤ 23 kg/m2) populations. Among the 694 participants, with a median age of 47 years and comprising 54% males, the prevalence of MASLD, MetALD, ALD, and cryptogenic SLD was 26%, 2%, 1%, and 2%, respectively. A remarkable difference was observed in the prevalence of SLD subclasses according to age, sex, and BMI. Subgroup analyses revealed heterogeneous demographic, clinical, and biochemical parameters between the SLD categories. Individuals with MetALD had higher gamma-glutamyl transferase levels, lower platelet counts, and higher fibrosis-4 index than did those with MASLD. Furthermore, the prevalence of non-obese and lean MASLD was 13% and 6%, respectively. This study provides preliminary information on the prevalence of SLD based on a new nomenclature in the Japanese population.

medicine, general & internal
Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population

Antonio De Vincentis,Federica Tavaglione,Shinichi Namba,Masahiro Kanai,Yukinori Okada,Yoichiro Kamatani,Samantha Maurotti,Claudio Pedone,Raffaele Antonelli Incalzi,Luca Valenti,Stefano Romeo,Umberto Vespasiani‐Gentilucci

DOI: https://doi.org/10.1111/apt.17953

IF: 9.524

2024-03-19

Alimentary Pharmacology & Therapeutics

Abstract:Summary Background and Aims The European Association for the Study of the Liver introduced a clinical pathway (EASL CP) for screening significant/advanced fibrosis in people at risk of steatotic liver disease (SLD). We assessed the performance of the first‐step FIB4 EASL CP in the general population across different SLD risk groups (MASLD, Met‐ALD and ALD) and various age classes. Methods We analysed a total of 3372 individuals at risk of SLD from the 2017–2018 National Health and Nutrition Examination Survey (NHANES17‐18), projected to 152.3 million U.S. adults, 300,329 from the UK Biobank (UKBB) and 57,644 from the Biobank Japan (BBJ). We assessed liver stiffness measurement (LSM) ≥8 kPa and liver‐related events occurring within 3 and 10 years (3/10 year‐LREs) as outcomes. We defined MASLD, MetALD, and ALD according to recent international recommendations. Results FIB4 sensitivity for LSM ≥ 8 kPa was low (27.7%), but it ranged approximately 80%‐90% for 3‐year LREs. Using FIB4, 22%–57% of subjects across the three cohorts were identified as candidates for vibration‐controlled transient elastography (VCTE), which was mostly avoidable (positive predictive value of FIB4 ≥ 1.3 for LSM ≥ 8 kPa ranging 9.5%–13% across different SLD categories). Sensitivity for LSM ≥ 8 kPa and LREs increased with increasing alcohol intake (ALD>MetALD>MASLD) and age classes. For individuals aged ≥65 years, using the recommended age‐adjusted FIB4 cut‐off (≥2) substantially reduced sensitivity for LSM ≥ 8 kPa and LREs. Conclusions The first‐step FIB4 EASL CP is poorly accurate and feasible for individuals at risk of SLD in the general population. It is crucial to enhance the screening strategy with a first‐step approach able to reduce unnecessary VCTEs and optimise their yield.

pharmacology & pharmacy,gastroenterology & hepatology

Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion.

The future of the firewall

The prevalence and predictors of metabolic dysfunction‐associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults

Amyloid or tau: the chicken or the egg?

Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population

Incidence of metabolic dysfunction‐associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study

The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD

Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents

Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function

Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care

Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score

Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis

Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up

Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States

Treatment of acute colonic pseudoobstruction (Ogilvie's syndrome) with cisapride.

New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study

A Health Checkup-Based Cross-Sectional Study

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population